ArticleBMJ public health2025
Differential impact of the COVID-19 pandemic on chlamydia and gonorrhoea cases among youth and young adults in Canada: an interrupted time series analysis.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Describing trends of sexually transmitted blood borne co-infections in Nova Scotia from 2019 to 2023.Canadian journal of public health = Revue canadienne de sante publique · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Globally, access to sexual health services declined during the COVID-19 pandemic. In Canada, pre-existing provincial differences in the organisation and delivery of sexual health services may have influenced how the pandemic affected testing and case detection. This study assessed the immediate and sustained impacts of the pandemic on reported chlamydia and gonorrhoea cases among youth and young adults in Ontario and British Columbia. Method: Laboratory-confirmed cases of chlamydia and gonorrhoea among individuals aged under 25 years were analysed using data from provincial surveillance sources from 2016 to 2021. Interrupted time series analyses were conducted using seasonal autoregressive integrated moving average models, stratified by sex and province. Sensitivity analyses examined trends excluding the initial 5 months of the pandemic (March-August 2020) and examined sustained impact through 2023. Results: Following the onset of COVID-19, chlamydia rates declined immediately by 39.13 cases per 100 000 population (95% CI -45.76 to -32.50) in Ontario and by 23.13 per 100 000 (95% CI -27.91 to -18.35) in British Columbia, corresponding to cumulative relative reductions of 42% and 29%, respectively. Gonorrhoea rates decreased by 3.25 per 100 000 (95% CI -4.72 to -1.77) in Ontario and by 1.70 per 100 000 (95% CI -3.92 to 0.51) in British Columbia, translating to cumulative relative reductions of 37% and 22%. Declines in reported cases were more pronounced among females for chlamydia, while males exhibited more sustained decreases over time. Sensitivity analyses confirmed these significant declines after excluding the initial pandemic period and persistent reductions through 2023. Conclusion: Reported chlamydia and gonorrhoea rates among youth and young adults declined substantially during the pandemic, with greater decreases in Ontario than in British Columbia. Sustained reductions suggest ongoing underdiagnosis and underreporting. British Columbia's smaller declines may be partly explained by broader access to their online testing services, GetCheckedOnline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.